Skip to main content

Prophylactic Treatment of Migraine With β-Blockers and Riboflavin: Differential Effects on the Intensity Dependence of Auditory Evoked Cortical Potentials

Buy Article:

The full text article is temporarily unavailable.

We apologise for the inconvenience. Please try again later.



To investigate the influence of different pharmacological treatments on the intensity dependence of auditory evoked cortical potentials in migraineurs.Background.–

Between attacks, patients with migraine show abnormalities in cortical information processing and decreased brain mitochondrial energy reserve. Both are most probably relevant for migraine pathogenesis, and they could be differentially modified by prophylactic drug therapy.

Design.–The intensity dependence of the auditory evoked cortical potentials is, on average, increased in migraine. We have studied this intensity dependence in 26 patients before and after a 4-month period of prophylaxis with beta-blockers (n=11, all migraine without aura; metoprolol or bisoprolol) or riboflavin (n=15, migraine without aura: 13, migraine with aura: 2). Recordings were performed at least 3 days before or after an attack.Results.–

After the treatment with beta-blockers, the intensity dependence of the auditory evoked cortical potentials was significantly decreased (before: 1.66 ± 1.02 μV/10 dB; after: 0.79 ± 1.06 μV/10 dB, P=.02). The decrease in intensity dependence was correlated significantly with clinical improvement (r=.69, P=.02). There was no change in intensity dependence after riboflavin treatment (before: 1.80 ± 0.81 μV/10 dB; after: 1.56 ± 0.83 μV/10 dB, P=.39), although the majority of patients showed improvement.Conclusions.–

These results confirm that beta-blockers and riboflavin act on two distinct pathophysiological mechanisms. Combining both treatments might enhance their efficacy without increasing central nervous system side effects.

Keywords: auditory evoked cortical potentials; beta-blockers; intensity dependence; migraine; prophylactic treatment; riboflavin

Document Type: Research Article

Publication date: 2000-01-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more